Algernon Pharmaceuticals Inc C.AGN

Question for the CEO, Mr. Moreau @ Algernon Pharmaceuticals

[BlaineBorg]

As of March 2020 to the present, here is the percentage of news releases individually targeting COVID-19, IPF & Chronic Cough, DMT, and Cancer.

COVID-19 - 63%

IPF & Chronic Cough - 6%

DMT - 10%

Cancer - Less than 1%

The remaining 20% of news releases targeted financing, webcast announcements, and other shiii.

Here is a portion of what the CEO stated in a SH interview just days ago.

SH: It’s been a busy year for Algernon, and investors are taking notice, yet you’ve had a bit of a roller coaster ride on the markets. What can you tell our investor audience regarding the current valuation of your stock and why you think it’s a good buy right now?

CJM: You know, I've said many times over the last couple of months that Algernon is not a COVID company, but if you sort of look at the stock and the trading, I think the COVID story did consume much of the oxygen in the room and has for the last period of time... 

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke | 2021-06-16 | Investing News | Stockhouse

So here's my question to Mr. Moreau:

If 75% of all news releases the past 16 Months (since March 2020) are targeted to COVID-19, why would the market think Algernon Pharmaceuticals isn't a "COVID" company?

Again, 75% of Algernon's messaging is COVID-19.  I mean you can try to flip the script, but the facts remain - Algernon is a COVID-19 company. COVID-19 is what has diluted the company and will continue to dilute the company for the foreseeable future without a partnership/sponsorship deal or data from the IPF/Chronic Cough study. DMT being in 2nd Place as far as "news" may likely take the forefront but without a conclusion to the COVID-19 "story" Algernon remains a COVID-19 company. None of the other stuff, including IPF and Chronic Cough has so far captured the market's attention. Nor do we know when the IPF and Chronic Cough data will become available. COVID-19 is the story. You don't need to know rocket science to know the market awaits EOP2 news. 

BB